ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 055,56
0,08%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Krystal Biotech Inc (KRYS)

  7. Krystal Biotech Inc (KRYS) Actualités

KRYS

Krystal Biotech (KRYS)

Krystal Biotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KRYS
DateHeureSourceTitreSymboleSociété
08/06/202400h09PR Newswire (US)KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:KRYSKrystal Biotech Inc
05/06/202413h00GlobeNewswire Inc.Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KRYSKrystal Biotech Inc
21/05/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRYSKrystal Biotech Inc
15/05/202413h00GlobeNewswire Inc.Krystal Biotech to Present at the American Thoracic Society 2024 International ConferenceNASDAQ:KRYSKrystal Biotech Inc
08/05/202413h00GlobeNewswire Inc.Krystal Biotech to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:KRYSKrystal Biotech Inc
06/05/202414h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRYSKrystal Biotech Inc
06/05/202414h09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:KRYSKrystal Biotech Inc
06/05/202414h00GlobeNewswire Inc.Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:KRYSKrystal Biotech Inc
02/05/202413h00GlobeNewswire Inc.Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:KRYSKrystal Biotech Inc
26/04/202413h00GlobeNewswire Inc.Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024NASDAQ:KRYSKrystal Biotech Inc
22/04/202413h00GlobeNewswire Inc.Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the LungNASDAQ:KRYSKrystal Biotech Inc
04/04/202413h00GlobeNewswire Inc.Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KRYSKrystal Biotech Inc
02/03/202402h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRYSKrystal Biotech Inc
28/02/202413h00GlobeNewswire Inc.Krystal Biotech to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:KRYSKrystal Biotech Inc
26/02/202419h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRYSKrystal Biotech Inc
26/02/202414h00GlobeNewswire Inc.Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:KRYSKrystal Biotech Inc
26/02/202413h59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KRYSKrystal Biotech Inc
26/02/202413h49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KRYSKrystal Biotech Inc
26/02/202411h57IH Market NewsU.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices RetreatNASDAQ:KRYSKrystal Biotech Inc
20/02/202413h00GlobeNewswire Inc.Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024NASDAQ:KRYSKrystal Biotech Inc
13/02/202413h00GlobeNewswire Inc.Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the LungNASDAQ:KRYSKrystal Biotech Inc
08/02/202413h00GlobeNewswire Inc.Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis BullosaNASDAQ:KRYSKrystal Biotech Inc
01/02/202413h00GlobeNewswire Inc.Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:KRYSKrystal Biotech Inc
04/01/202413h00GlobeNewswire Inc.Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®NASDAQ:KRYSKrystal Biotech Inc
19/12/202313h00GlobeNewswire Inc.Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)NASDAQ:KRYSKrystal Biotech Inc
27/11/202313h00GlobeNewswire Inc.Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis BullosaNASDAQ:KRYSKrystal Biotech Inc
09/11/202313h00GlobeNewswire Inc.Krystal Biotech to Present at the Stifel 2023 Healthcare ConferenceNASDAQ:KRYSKrystal Biotech Inc
06/11/202313h00GlobeNewswire Inc.Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KRYSKrystal Biotech Inc
30/10/202312h00GlobeNewswire Inc.Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023NASDAQ:KRYSKrystal Biotech Inc
28/09/202313h00GlobeNewswire Inc.Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines ConferenceNASDAQ:KRYSKrystal Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:KRYS

Dernières Valeurs Consultées

EU
HO
Thales
EU
GLE
Societe Generale
EU
DG
Vinci
FTSE
UKX
FTSE 100
EU
SGO
Cie de SaintGobain
EU
BN
Danone
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
ML
Michelin
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
EU
CS
Axa
EU
ORA
Orange
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés